China Medical GatewayLoading your healthcare gateway…

Breast Cancer in China

Overview

Breast cancer is the most common cancer in women. Molecular subtyping — hormone-receptor and HER2 status — now personalizes every treatment decision, and early-stage disease is curable in the large majority of patients.

China’s leading breast centers integrate screening, oncoplastic surgery and precision drug therapy under one roof, with reconstruction options that restore form at the same operation as cancer removal.

Symptoms & Signs

A painless breast lump or area of thickening

Skin dimpling, redness, scaling or nipple inversion

Nipple discharge, sometimes blood-stained

A newly visible asymmetry or change in breast contour

Swollen lymph nodes in the armpit

Screening mammography frequently detects cancers before any symptom develops

Diagnosis

Mammography with digital tomosynthesis (3D) and targeted breast ultrasound

Breast MRI for dense breasts, implant evaluation or staging

Core needle biopsy with hormone-receptor, HER2 and Ki-67 testing

Genomic risk assays (e.g. 21-gene-class) guiding chemotherapy decisions in early disease

Pathology review confirming subtype and tumor extent

Genetic counseling and BRCA testing for patients with strong family history

Treatment Options

Breast-conserving lumpectomy with radiotherapy for suitable early tumors

Mastectomy with immediate reconstruction — implant or autologous (DIEP flap) — when conservation is not possible

Sentinel lymph node biopsy sparing unnecessary axillary dissection

Neoadjuvant therapy shrinking larger tumors before surgery and providing response information

Endocrine therapy for hormone-receptor-positive disease over 5-10 years

Anti-HER2 targeted therapy, chemotherapy and immunotherapy according to subtype

Advanced Technologies & Novel Drug

3D tomosynthesis and vacuum-assisted breast biopsy

Oncoplastic surgical techniques and microsurgical reconstruction

Intraoperative radiotherapy and hypofractionated whole-breast IMRT

Dual-tracer sentinel node mapping

Novel CDK4/6 inhibitors, HER2 antibody-drug conjugates and PARP inhibitors available at major centers

Hospital & Specialist

Return to Home